SKNJCT-003 Phase 2 Data Shows 55% Complete Response, Paving Registrational Path for Medicus Pharma
Summary
Medicus Pharma announced positive results from an expanded Phase 2 data analysis for its Doxorubicin Microneedle Array (D-MNA), SKNJCT-003, for nodular basal cell carcinoma. The 200µg cohort achieved a 55% complete response at Day 57, demonstrating a positive dose-response and emerging as a "registrational grade lead regimen." This significant clinical development comes amidst a challenging period for Medicus Pharma, which recently received a Nasdaq delisting notice, expanded a highly dilutive ATM offering to $50 million, and filed for an aggressive reverse stock split. For a micro-cap biotech facing severe financial and compliance issues, strong Phase 2 data indicating a clear path to registration is a critical positive catalyst, providing much-needed scientific validation and a potential future value driver. Investors will now watch for the company's End-of-Phase 2 (EOP2) discussions with the FDA and any subsequent plans for a Phase 3 trial or partnership, as well as how this news impacts its ability to address its financial and listing challenges.
At the time of this announcement, MDCX was trading at $0.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.25 to $8.94. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.